Lobbying Information
Subject Matters
- Aboriginal Health
- Animal Health
- Consumer Issues
- Cross-border Trade
- Federally-funded Health Benefits Program
- Fiscal Policies and Regulations
- Health
- Health Research Policies, Regulations and Ethics
- Industry
- Intellectual Property
- International Trade
- Pharmaceutical Policies and Regulations
- Regional Development
- Science and Technology
- Taxation and Finance
Subject Matter Details
Legislative Proposal, Bill or Resolution
- Bill C-6, Canada Consumer Product Safety Act (former Bill C-52) as it relates to creating a new system to regulate consumer products that pose, or might reasonably be expected to pose, a danger to human health and safety.
Legislative Proposal, Bill or Resolution, Regulation
- Food and Drugs Act & Regulations as it relates to Drug Export Restrictions and cross border trade.
- The upcoming Food and Drugs Act Modernization legislative proposal (Act and Regulations) as it relates to improving the efficiency of the drug review and approval process.
Policies or Program
- Canadian Institute of Health Researchers (CIHR) and other Research Oriented Spending Programs as it relates to private/public research and development partnerships.
- Common Drug Review as it relates to reimbursement recommendations decision-making process and framework.
- Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries
- Federal Tobacco Control Strategy as it relates to smoking cessation policy and program initiatives
- Science and Technology Strategy, Advantage Canada or any Government policy or program initiatives to support Research and Development in Canada, and advocate for the development of a Biopharma sectoral strategy in support of more research & development in Canada
Policies or Program, Regulation
- Subsequent Entry Biologics (SEBs): seeking an approval framework supported and protected by Regulations in harmonization with the direction taken by the European Union for instance
Regulation
- Food and Drugs Act Regulations as it relates to submission & manufacturing approvals of animal health products (Veterinary Drug Directorate).
- Patented Medicine Prices Review Board (PMPRB) Regulations as it relates to reporting requirements and pricing guidelines.
- Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for therapeutic products.
Communication Techniques
-
Written communication
-
Oral communication
-
As part of Industry Associations and Delegations eg. Rx&D, BIOTECanada, Chamber of Commerce
Government Institutions
-
Aboriginal Affairs and Northern Development Canada
-
Agriculture and Agri-Food Canada (AAFC)
-
Canadian Agency for Drugs and Technologies in Health (CADTH)
-
Canadian Expert Drug Advisory Committee (CEDAC)
-
Canadian Food Inspection Agency (CFIA)
-
Canadian Institute for Health Research
-
Canadian International Development Agency (CIDA)
-
Federal Office of Regional Development – Quebec (FORD[Q])
-
Finance Canada (FIN)
-
Foreign Affairs and International Trade Canada (DFAITC)
-
Health Canada (HC)
-
Industry Canada
-
Justice Canada (JC)
-
Members of the House of Commons
-
National Defence (DND)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Public Works and Government Services Canada
-
Revenue Canada (RC)
-
Senate of Canada
-
Treasury Board Of Canada Secretariat (TBS)
-
Veterans Affairs Canada (VAC)
In-house Corporation Details
Description of activities
Pfizer discovers, develops, manufactures and markets prescription medicines for humans and animals.
Responsible officer name and position during the period of this registration
Paul Lévesque,
Président et chef de la direction
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
17,300 TRANS-CANADA HIGHWAY
KIRKLAND, QC H9J 2M5
Canada
Telephone number:
514-426-7417
Fax number:
514-426-6835
Parent Company Information
- PFIZER INC
-
235 EAST 42ND STREET
NEW YORK, NY 10017-5755
United States of America
Subsidiary Beneficiary Information
Pfizer Canada ULC does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Dr. Ghislain Boudreau,
Vice President, Public Affairs & Stekeholders Relations |
No public offices held
- Terry Gunter,
Animal Health Director |
No public offices held
- Paul Lévesque,
President & CEO |
No public offices held
- Darren Noseworthy,
Vice President & General Counsel |
No public offices held
- Bernard Prigent,
Vice President and Medical Director |
Public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- David Fortier,
Director, Strategy & Health Policy |
No public offices held
- Steven Hogue,
Associate Director, Federal Relations |
Public offices held
- Mark Legault,
Senior Manager, Pricing |
No public offices held
